Research Forums

Join our monthly Virtual Research Forums to learn more about our research agenda and the studies we are currently funding.

Our founder Clyde Campbell will be hosting these forums each month where we will share regular updates on the current research we are funding, progress being made and new discoveries. Each month we will invite a guest research team to outline their study rationale, what they are hoping to achieve and any progress they have made.

There will also be an opportunity to ask questions of the researchers after their presentation.

 

April Research Forum

Researcher: Fazel Shabanpoor, PhD

Research Institute: The Florey Institute of Neuroscience and Mental Health

Date: Thursday 21 April

Time: 5pm – 6pm

If you missed the April Research Forum, you can watch the recording here:

BRAIN-PENETRATING ANTISENSE OLIGONUCLEOTIDE TO DOWN-REGULATE ALPHA-SYNUCLEIN

Antisense oligonucleotides (ASOs) offer a new therapeutic strategy in Parkinson’s disease (PD) because they can be readily targeted to genes causally linked to PD development or progression. Consequently, they may treat the underlying pathology of PD, not just symptoms, and hence profoundly alter its relentless progression and impact on patients.

To be effective in PD, ASOs must get into the brain, however ASOs show almost no brain penetration following intravenous or subcutaneous administration. A requirement for intrathecal administration would severely limit the number of PD patients who could benefit from ASO therapies due to cost, access and capacity of clinical services.

This project will develop an ASO therapy that reduces alpha-synuclein expression in the brain following subcutaneous administration. The target product brings together two proven technologies – an ASO that has already shown efficacy in downregulating human alpha-synuclein expression following intracranial injection in transgenic mice, conjugated to our proprietary brain-penetrating peptide (BPP) that we have shown enables other ASOs to get into the brain following peripheral administration in neonatal and adult mice.

This project will assess the ability of BPP-ASO conjugates to downregulate human alpha-synuclein mRNA and protein expression in vitro in human cell lines and in vivo in brains of adult transgenic mice overexpressing human alpha-synuclein following subcutaneous injection. We will optimise the chemistry of the ASO and BPP to select a lead BPP-ASO candidate and assess its in vivo pharmacokinetics (dose-effect, time-course) and toxicity.

 

REGISTER TODAY

Review Previous Forums

SIGN UP FOR EMAIL UPDATES

GET PARKINSON'S RESEARCH NEWS, FOUNDATION UPDATES, INVITATIONS TO EVENTS AND MORE.